Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen

Journal of Clinical Microbiology

Volumn 50, Issue 9, 2012, Pages 3096-3098

  Tuaillon, Edouard ^a,b   Lozano, C ^b   Kuster, N ^b   Poinso, A ^b   Kania, D ^a,c   Nagot, N ^a,b   Mondain, A M ^b   Pageaux, G P ^d   Ducos, J ^a,b   Van De Perre, P ^a,b   Reynes, J ^b,e  

^a UNIV MONTPELLIER   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c CENTRE MURAZ   (Burkina Faso)

^d INSERM   (France)

^e UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; GENE REPRESSION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MIXED INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; COINFECTION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; ORGANOPHOSPHONATES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865169790     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00971-12     Document Type: Article

References (11)

1. Altman DG, Bland JM. 2003. Interaction revisited: the difference between two estimates. BMJ 326:219. (Pubitemid 36143396)
2. Brunetto MR, et al. 2009. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49:1141-1150.
3. Chan HL, et al. 2010. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52:1232-1241.
4. Hadziyannis SJ, et al. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131:1741-1743.
5. Heathcote EJ, et al. 2011. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140:132-143.
6. Marcellin P, et al. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351:1206-1217. (Pubitemid 39296307)
7. Maylin S, et al. 2012. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 26:939-949.
8. Moucari R, et al. 2009. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151-1157.
9. Simonetti J, et al. 2010. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51:1531-1537.
10. Thibault V, et al. 2011. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir. Ther. 16:199-205.
11. Tuaillon E, et al. 2012. Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes. PLoS One 7:e32143. doi:10.1371/journal.pone.0032143.